MONALEESA-3 is a randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer who have received no or only one line of prior endocrine treatment. Here, ERBB2 is linked to breast cancer.